* United Therapeutics Corp UTHR.OQ reported quarterly
adjusted
earnings of $6.39 per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of $5.38. The mean expectation of
thirteen analysts for the quarter was for earnings of $6.42 per
share. Wall Street expected results to range from $5.41
to $7.41 per share.
* Revenue rose 22.9% to $748.90 million from a year ago;
analysts
expected $722.58 million.
* United Therapeutics Corp's reported EPS for the quarter
was
$6.39.
* The company reported quarterly net income of $309.1
million.
* United Therapeutics Corp shares had fallen by 1.5% this
quarter and gained 60.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.1%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for United
Therapeutics Corp is $382.06
This summary was machine generated from LSEG data October 30 at
03:11 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 6.42 6.39 Missed
Jun. 30 2024 6.40 5.85 Missed
Mar. 31 2024 5.65 6.17 Beat
Dec. 31 2023 4.19 4.36 Beat